Company intelligence / Profile preview

Carise Pharmaceuticals

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Carise Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation small molecule therapeutics for cancer and other life-threatening diseases. Based in Suzhou, China, the company focuses on targeting the RAS/MAPK signaling pathway and other high-value oncogenic drivers. Its lead candidate, CRS-001, is a potent and selective KRAS G12C inhibitor currently undergoing clinical evaluation for solid tumors. Carise utilizes a structure-based drug design approach to build a robust pipeline of precision medicines aimed at overcoming drug resistance and improving patient outcomes.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Carise Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carise Pharmaceuticals.

Explore the full profile